The size of the global pancreatic cancer therapeutics market is estimated to be growing at a CAGR of 7.54% from 2022 to 2027. The size of the market is projected to be worth USD 3.73 billion by 2027 from USD 2.59 billion in 2022.
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of the pancreas. Pancreatic cancer is identified as the uncontrolled growth of cells, i.e., malignant cells in the pancreas tissues. The malignant cells lead to tumor formation in the pancreas, which deters the organ's normal functioning.
The occurrence and mortality rate of pancreatic cancer is more in men than in women. SEER estimates that pancreatic cancer accounts for around seven percent of the total cancer deaths in the US annually.
The increasing pervasiveness of pancreatic cancer in developed nations due to the absence of therapeutic procedures for early-stage detection pushes the pancreatic cancer market.
The significant incidence of pancreatic cancer that initiates germline mutations is also expected to accelerate the market's growth rate. The growing demand for targeted therapy is another factor propelling the growth of the pancreatic cancer market. Targeted therapy singles out particular receptors present in the cancer cells and do not affect the body's healthy peripheral cells, unlike the conventional therapeutics' method like chemotherapy. The increasing pervasiveness of pancreatic cancer and increasing demand for targeted therapy drives the pancreatic cancer market.
Affordable and efficient technologies for the timely diagnosis of pancreatic cancer are yet to develop fully. Therefore, most pancreatic cancer patients are being diagnosed at an advanced level of the disease. In the advanced stage of pancreatic cancer, the therapy options are limited, leading to high mortality rates. These factors are restricting the growth of the market for pancreatic cancer therapeutics. Surveys show that only a small percentage (about 12% to 15%) of patients is diagnosed immediately enough to be treated with surgical methods, drugs, and chemotherapy.
Impact of COVID-19 on the global pancreatic cancer market:
The covid-19 pandemic has impacted the global Pancreatic Cancer Treatment Market significantly due to cancer patients being more prone to the coronavirus. Thus, they require more professional care and assistance.
The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to rethink patient cancer care deeply.
Market Size Available
2021 to 2027
2022 to 2027
By Type, Treatment Type, End Users, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
Eli Lilly, Amgen Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp.
This research report on the global pancreatic cancer market has been segmented and sub-segmented based on the cancer type, treatment type, end-users, and region.
Pancreatic Cancer Market - By Cancer Type:
Based on the cancer type, most of the pancreatic cancer patients diagnosed in the world belong to the exocrine class. Therefore, the segment currently governs the market. The endocrine type of cancers, although less common, is still anticipating effective treatment modalities.
The investment in research and development is significant in both types of cancers. However, the growing prevalence and increasing reach of innovative techniques in developing countries are the factors anticipated to drive the exocrine segment's growth during the forecast period.
Pancreatic Cancer Market - By Treatment Type:
Pancreatic Cancer Market - By End User:
Based on end-user, the Hospital segment is the significant revenue-generating segment in the global pancreatic cancer therapeutics market, which is supposed to continue in the forecast years.
Pancreatic Cancer Market - By Region:
Globally, North America is the largest market for pancreatic cancer. The prevalence of pancreatic cancer is more in North American countries, with the U.S. having the highest number of pancreatic cancer patients worldwide. North America dominated the pancreatic cancer treatment industry, with the largest revenue share in 2019. It is mainly attributed to the improved healthcare infrastructure, high adoption of pancreatic treatment procedures, and a large target population. Besides, an increasing incidence of pancreatic cancer is aggressively propelling the demand for treatment options.
Europe is expected to be the second-largest market for pancreatic cancer.
Asia-Pacific is anticipated to be the fastest-growing region across the globe. On the other hand, Asia Pacific is expected to witness the fastest growth during the forecast period. The presence of well-established hospitals and critical care centers and a large population suffering from pancreatic cancer would boost the market's development in the Asia Pacific region. Furthermore, with the growing number of pancreatic cancer cases in the Asia Pacific region, the diagnosis and treatment of pancreatic cancer must adhere to the same regimen as in western countries.
KEY MARKET PLAYERS:
Key companies leading the global pancreatic cancer market profiled in the report are Eli Lilly, Amgen Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc., and NewLink Genetics Corp.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Treatment
5.1.4 Radiation Therapy
5.1.6 Y-o-Y Growth Analysis, By Type of Treatment
5.1.7 Market Attractiveness Analysis, By Type of Treatment
5.1.8 Market Share Analysis, By Type of Treatment
5.2.2 Exocrine Pancreas Cancer
5.2.3 Endocrine Pancreas Cancer
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3.4 Research Institutes
5.3.6 Y-o-Y Growth Analysis, By End-users
5.3.7 Market Attractiveness Analysis, By End-users
5.3.8 Market Share Analysis, By End-users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Type of Treatment
220.127.116.11 By Type
18.104.22.168 By End-users
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Type of Treatment
188.8.131.52 By Type
184.108.40.206 By End-users
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Type of Treatment
22.214.171.124 By Type
126.96.36.199 By End-users
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Eli Lilly
8.1.2 Type of Product
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen, Inc.
8.3 Celgene Corp.
8.4 F. Hoffmann-La Roche
8.5 Clovis Oncology Inc.
8.7 Novartis AG
8.8 Threshold Pharmaceuticals Inc.
8.9 Aduro BioTech Inc.
8.10 Infinity Pharmaceuticals Inc.
8.11 NewLink Genetics Corp.
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.